Fundraising Fox

4TEEN4 Pharmaceuticals GmbH

Founded 2013 · 37 employees on LinkedIn · 2 known investors

4TEEN4 Pharmaceuticals develops invobenitug (procizumab), a humanized monoclonal antibody that neutralizes circulating Dipeptidyl Peptidase 3 (cDPP3) to reverse life-threatening shock and restore organ function. The company uses a biomarker-driven approach for critical care patients, with a clinical program focused on cardiogenic shock.

BiotechHealthtechMedical Devices

Investors · 2

Brandenburg KapitalPotsdam · $108K – $5.4M
Görlich GruppeBerlin

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Abingdon Health provides update on 4TEEN4 diagnostic partnership By Investing.cominvesting.com · May 20264TEEN4 erweitert Series-C-Finanzierungsrunde auf 55 Mio. EUR - VC Magazinvc-magazin.de · Nov 20254TEEN4 Extends Series C Financing Round to €55 Million, Supporting Expanded Clinical Development of Procizumab in Cardiogenic Shockglobenewswire.com · Nov 2025Active fund | Goerlich Groupgoerlich.de · Oct 20244TEEN4 Pharmaceuticals GmbH announced that it has received funding from Boditech Med Inc. | MarketScreenermarketscreener.com · Feb 2024Biotech Startup 4TEEN4 Pharmaceuticals Closes EUR 7 Million Series A Financingfinance.yahoo.com · Dec 2019

Frequently asked questions

What does 4TEEN4 Pharmaceuticals GmbH do?
4TEEN4 Pharmaceuticals develops invobenitug (procizumab), a humanized monoclonal antibody that neutralizes circulating Dipeptidyl Peptidase 3 (cDPP3) to reverse life-threatening shock and restore organ function. The company uses a biomarker-driven approach for critical care patients, with a clinical program focused on cardiogenic shock.
Who are 4TEEN4 Pharmaceuticals GmbH's investors?
4TEEN4 Pharmaceuticals GmbH's investors include Brandenburg Kapital, Görlich Gruppe.